SMC2

Across TCGA pan-cancer cohorts, SMC2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SMC2 data layer compared with 25 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher SMC2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SMC2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and PDAC show a favorable association.

LSCC, LUAD, and PDAC are the cancer types where SMC2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	II,III,IV	0.886	0.527	.002	29	view →
LUAD	OS	Quartile	II,III,IV	0.307	0.871	.027	4	view →
PDAC	DFS	Median	IV	0.934	0.250	.024	3	view →
HNSC	OS	Tertile	All	0.761	0.888	.024	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SMC2–LSCC (DFS)

Open the LSCC breakdown →